Full video transcriptClick to expand
Auto-generated transcript of @dr.leytonmd's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00It depends on your schedule, whether you're in a U.S. or in the U.S. or in the U.S.
- 0:07or in the U.S.
- 0:09In a U.S. we have to figure out a way to do this.
- 0:13We can use the same as a U.S.
- 0:18in a U.S. or a U.S. or a U.S. or a U.S. or a U.S. or a U.S. or an U.S. or a U.S.
- 0:54in the appeal.
- 0:55Ctns alguna alguna al mericamento de jalones comentar e tester eres fondient.
Liraglutide for diabetes and obesity: what the evidence says
Quick answer
The video caption identifies liraglutide's two primary clinical applications, type 2 diabetes and obesity, which accurately reflects its FDA-approved indications under the brand names Victoza and Saxenda. The transcript itself is too fragmented to evaluate for clinical accuracy, but the implied framing aligns with established trial evidence including the LEADER cardiovascular outcomes trial and the SCALE weight management program. Liraglutide remains a valid therapeutic option but is increasingly used in cases where newer weekly GLP-1 agents are not appropriate or accessible.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Liraglutide for diabetes and obesity: what the evidence says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Liraglutide for diabetes and obesity: what the evidence says is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Liraglutide for diabetes and obesity: what the evidence says" from Dr.Leytonmd. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video caption identifies liraglutide's two primary clinical applications, type 2 diabetes and obesity, which accurately reflects its FDA-approved indications under the brand names Victoza and Saxenda.
The reason this review is not generic is the source wording and the canonical claim label "glp1 te explico para que sirve la liraglutide liraglutida diabete." In this clip, the useful excerpt is: "It depends on your schedule, whether you're in a U." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The video caption identifies liraglutide's two primary clinical applications, type 2 diabetes and obesity, which accurately reflects its FDA-approved indications under the brand names Victoza and Saxenda.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video caption identifies liraglutide's two primary clinical applications, type 2 diabetes and obesity, which accurately reflects its FDA-approved indications under the brand names Victoza and Saxenda. The transcript itself is too fragmented to evaluate for clinical accuracy, but the implied framing aligns with established trial evidence including the LEADER cardiovascular outcomes trial and the SCALE weight management program. Liraglutide remains a valid therapeutic option but is increasingly used in cases where newer weekly GLP-1 agents are not appropriate or accessible.
- Liraglutide has two FDA-approved forms: Victoza (1.2-1.8 mg for type 2 diabetes) and Saxenda (3.0 mg for obesity), same molecule at different doses.
- The LEADER trial (Marso et al., 2016, NEJM) found a 13% reduction in major adverse cardiovascular events in high-risk type 2 diabetes patients over 3.8 years.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Liraglutide has two FDA-approved forms: Victoza (1.2-1.8 mg for type 2 diabetes) and Saxenda (3.0 mg for obesity), same molecule at different doses.
- The LEADER trial (Marso et al., 2016, NEJM) found a 13% reduction in major adverse cardiovascular events in high-risk type 2 diabetes patients over 3.8 years.
- The SCALE trial (Pi-Sunyer et al., 2015, NEJM) showed roughly 8% average weight loss with liraglutide 3.0 mg over 56 weeks, compared to about 2.6% with placebo.
- Semaglutide 2.4 mg weekly produced approximately 14.9% mean weight loss in STEP 1 (Wilding et al., 2021, NEJM), outperforming liraglutide on this endpoint.
- Liraglutide carries an FDA boxed warning for thyroid C-cell tumors based on rodent data; it should not be used in patients with a history of medullary thyroid carcinoma.
- Compounded liraglutide is not equivalent to FDA-approved Victoza or Saxenda. Manufacturing standards, potency, and sterility differ and are not federally regulated in the same way.
- Liraglutide manages diabetes and obesity while in use. It does not cure either condition, and discontinuation is associated with weight regain based on extension data from SCALE.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @dr.leytonmd actually say?
Honestly, not much that we can verify. The transcript captured here is largely incoherent, a string of repeated phrases and fragmented Spanish that does not produce a clear medical claim. The caption promises an explanation of what liraglutide is used for, covering diabetes and obesity, but the spoken content doesn't deliver a coherent argument we can pin down and check.
What we can do is fact-check the implied premise of the video: that liraglutide is a useful tool for type 2 diabetes and obesity management. That claim, at least, is well-grounded in the medical literature, and it's worth unpacking what the evidence actually says versus what tends to circulate on health TikTok about GLP-1 receptor agonists as a category.
Does the science back this up?
Yes, the core premise holds. Liraglutide has two FDA-approved indications with solid trial data behind both of them. The short version: it works for blood sugar control in type 2 diabetes, and it produces meaningful weight loss in people with obesity, though it has largely been overshadowed by newer agents.
The LEADER trial (Marso et al., 2016, New England Journal of Medicine) followed over 9,000 patients with type 2 diabetes and established cardiovascular risk. Liraglutide reduced major adverse cardiovascular events by 13% compared to placebo over a median of 3.8 years. That was a significant result and helped cement GLP-1 agonists as a class with benefits beyond glucose control.
For weight loss, the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) showed that liraglutide 3.0 mg daily, marketed as Saxenda, produced an average weight loss of about 8% of body weight over 56 weeks, compared to roughly 2.6% with placebo. Meaningful, but modest compared to what semaglutide trials have since shown.
What did they get wrong (or right)?
We can't fairly accuse @dr.leytonmd of getting specific facts wrong when the transcript doesn't contain specific facts. The video caption correctly identifies the two main clinical use cases, diabetes and obesity, which is accurate framing. No credit for nuance here, but no penalty for misinformation either, at least not from what we can evaluate.
What the video seems to miss by omission, based on the hashtags and category alone, is any mention of where liraglutide sits today relative to semaglutide and tirzepatide. Liraglutide is a daily injection. Semaglutide is once weekly and outperforms it on weight loss endpoints. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4 mg produced roughly 14.9% average weight loss versus the 8% range seen with liraglutide. That context matters when someone watches a TikTok about liraglutide and wonders whether it's the right option for them.
What should you actually know?
Liraglutide is a legitimate, well-studied medication with two distinct FDA-approved forms: Victoza for type 2 diabetes management and Saxenda for chronic weight management. They are the same molecule at different doses, and that distinction matters clinically.
It works by mimicking GLP-1, a hormone released after eating. That mechanism slows gastric emptying, reduces appetite signaling in the brain, and stimulates insulin release in a glucose-dependent way, meaning it doesn't cause hypoglycemia on its own the way older diabetes drugs can.
- Liraglutide is not a cure for diabetes or obesity. It manages these conditions while in use.
- Common side effects include nausea, vomiting, and diarrhea, particularly early in treatment.
- The FDA label carries a boxed warning about thyroid C-cell tumors observed in rodent studies. The clinical relevance in humans remains under study, but patients with a personal or family history of medullary thyroid carcinoma should not use it.
- Compounded liraglutide is not the same as FDA-approved Victoza or Saxenda. Potency, sterility, and formulation are not guaranteed in compounded versions.
If you're deciding between GLP-1 options, that conversation belongs with a licensed prescriber who knows your full medical history, not a TikTok comment section.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr.Leytonmd · TikTok creator
10.8K views on this video
Te explico para que sirve la LIRAGLUTIDE #liraglutida #diabetes #obesidad #creatorsearchinsight #diabetestipo2
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about liraglutide has two fda-approved forms: victoza (1.2-1.8 mg for type?
Liraglutide has two FDA-approved forms: Victoza (1.2-1.8 mg for type 2 diabetes) and Saxenda (3.0 mg for obesity), same molecule at different doses.
What does the video say about the leader trial (marso et al., 2016, nejm) found a?
The LEADER trial (Marso et al., 2016, NEJM) found a 13% reduction in major adverse cardiovascular events in high-risk type 2 diabetes patients over 3.8 years.
What does the video say about the scale trial (pi-sunyer et al., 2015, nejm) showed roughly?
The SCALE trial (Pi-Sunyer et al., 2015, NEJM) showed roughly 8% average weight loss with liraglutide 3.0 mg over 56 weeks, compared to about 2.6% with placebo.
What does the video say about semaglutide 2.4 mg weekly produced approximately 14.9% mean weight loss?
Semaglutide 2.4 mg weekly produced approximately 14.9% mean weight loss in STEP 1 (Wilding et al., 2021, NEJM), outperforming liraglutide on this endpoint.
What does the video say about liraglutide carries an fda boxed warning for thyroid c-cell tumors?
Liraglutide carries an FDA boxed warning for thyroid C-cell tumors based on rodent data; it should not be used in patients with a history of medullary thyroid carcinoma.
What does the video say about compounded liraglutide?
Compounded liraglutide is not equivalent to FDA-approved Victoza or Saxenda. Manufacturing standards, potency, and sterility differ and are not federally regulated in the same way.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dr.Leytonmd, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.